Illinois General Assembly

  Bills & Resolutions  
  Compiled Statutes  
  Public Acts  
  Legislative Reports  
  IL Constitution  
  Legislative Guide  
  Legislative Glossary  

 Search By Number
 (example: HB0001)
Search Tips

Search By Keyword

Public Act 103-0030


Public Act 0030 103RD GENERAL ASSEMBLY



Public Act 103-0030
HB2350 EnrolledLRB103 26427 BMS 52790 b

    AN ACT concerning regulation.
    Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
    Section 5. The Illinois Insurance Code is amended by
changing Section 356u as follows:
    (215 ILCS 5/356u)
    Sec. 356u. Pap tests and prostate cancer screenings.
    (a) A group policy of accident and health insurance that
provides coverage for hospital or medical treatment or
services for illness on an expense-incurred basis and is
amended, delivered, issued, or renewed after January 1, 2024
shall provide coverage, without imposing a deductible,
coinsurance, copayment, or any other cost-sharing requirement,
for all of the following:
        (1) An annual cervical smear or Pap smear test for all
    female insureds.
        (2) An annual prostate cancer screening for male
    insureds upon the recommendation of a physician licensed
    to practice medicine in all its branches for:
            (A) asymptomatic individuals men age 50 and over;
            (B) African-American individuals men age 40 and
        over; and
            (C) individuals men age 40 and over with a family
        history of or genetic predisposition to prostate
        (3) Surveillance tests for ovarian cancer for female
    insureds who are at risk for ovarian cancer.
    (b) This Section shall not apply to agreements, contracts,
or policies that provide coverage for a specified disease or
other limited benefit coverage.
    (c) This Section does not apply to coverage of prostate
cancer screenings to the extent such coverage would disqualify
a high-deductible health plan from eligibility for a health
savings account pursuant to Section 223 of the Internal
Revenue Code.
    (d) For the purposes of this Section:
    "At risk for ovarian cancer" means:
        (1) having a family history (i) with one or more
    first-degree relatives with ovarian cancer, (ii) of
    clusters of women relatives with breast cancer, or (iii)
    of nonpolyposis colorectal cancer; or
        (2) testing positive for BRCA1 or BRCA2 mutations.
    "Prostate cancer screening" means medically viable methods
for the detection and diagnosis of prostate cancer, including
a digital rectal exam and the prostate-specific antigen test
and associated laboratory work. "Prostate cancer screening"
includes medically necessary subsequent follow-up testing as
directed by a health care provider, including, but not limited
        (1) urinary analysis;
        (2) serum biomarkers; and
        (3) medical imaging, including, but not limited to,
    magnetic resonance imaging.
    "Surveillance tests for ovarian cancer" means annual
screening using (i) CA-125 serum tumor marker testing, (ii)
transvaginal ultrasound, (iii) pelvic examination.
(Source: P.A. 102-1073, eff. 1-1-23.)
    Section 99. Effective date. This Act takes effect January
1, 2025.

Effective Date: 1/1/2025